Company is not issuing formal guidance for fiscal 2027 due to recent CEO transition
Overview
U.S. health and wellness firm's fiscal Q4 revenue fell 23%, missing analyst expectations
Adjusted EPS for fiscal Q4 declined and missed analyst expectations
Company cites lower order volume, smaller average orders, and weaker MindBody GLP-1 sales for declines
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for LifeVantage Corp is $7.00, about 5.9% above its August 26 closing price of $6.61
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 8 three months ago
Result drivers and key details
Order volume and size - Co said revenue decline was mainly due to fewer orders from active accounts and lower average order size
- Co cited lower sales of MindBody GLP-1 System cycling a strong prior-year quarter as a factor in revenue drop
LFVN•
